LPTX Overview
Upcoming Projects (LPTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (LPTX)
-
Discussing investigational therapies in CRC, including DKN-01+bevacizumab+chemo (triple combo) in 2nd line from Leap Therapeutics and onvansertib, a PLK1 inhibitor in 1st and 2nd line from Cardiff Oncology.
Tickers: CRDF, LPTX
Executed On: Apr 30, 2024 at 10:30 AM EDT -
Discussing novel therapeutics to treat gastric cancer/GEJ Adenocarcinoma, with a focus Leap Therapeutics' DKN-01 (anti-DKK1) on top of PD-1 (tislelizumab) and chemotherapy in 1L GEA patients
Ticker: LPTX
Executed On: Mar 21, 2024 at 11:30 AM EDT -
Discussing novel therapeutics to treat gastric cancer/GEJ Adenocarcinoma, including Leap Therapeutics' DKN-01 (anti-DKK1) on top of PD-1 and chemo, as well as Claudin 18.2 (Zolbetuximab from Astellas, & SYSA1801 from Elevation Oncology)
Tickers: LPTX, ELEV, ALPMY
Executed On: Jun 12, 2023 at 01:00 PM EDT
Expired Projects (LPTX)
Upcoming & Overdue Catalysts (LPTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (LPTX)
-
Macrocure (MCUR) Presents Phase 1 Data on Lead Candidate DKN-01 + Chemotherapy in Advanced Biliary Cancer
Tickers: MCUR, LPTX
Occurred on: Oct 08, 2016
Strategic Initiatives (LPTX)
-
Leap Therapeutics (LPTX) and BeiGene (BGNE) Announce Exclusive Option and License Agreement for DKN-01 + $27 Million Equity Financing
Tickers: LPTX, BGNE
Announcement Date: Jan 03, 2020
